C2N Diagnostics, LLC, a leading developer of Alzheimer’s disease-specific fluid biomarker tests, has secured a new investment of $15 million from the GHR Foundation to advance the development of tests focused on tau tangle pathology. Tau tangles are a key element of Alzheimer’s disease and are thought to significantly influence the disease's progression.

The next generation of tests aims to provide a less invasive and more accessible alternative to traditional tau PET imaging. These tests will utilise a combination of tau-based blood biomarkers, including MTBR-tau, which are vital indicators of the pathological tau tangles and neurites linked to Alzheimer’s disease.

This approach could enhance the differential diagnosis of Alzheimer’s in individuals showing cognitive symptoms, help stage the disease biologically, and assist in the creation of tau-targeted therapies by offering insights into tau pathology.

C2N has previously introduced a proprietary cerebrospinal fluid test for research purposes that measures MTBR-tau. The latest funding from GHR follows a recent announcement that C2N has received up to $7.025 million from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator initiative.

This investment aims to develop a decentralized clinical mass spectrometry solution to facilitate high-performance Alzheimer’s testing globally.

The GHR Foundation has previously supported the launch of C2N’s current blood test, the PrecivityAD2, which became available for clinical use in 2023. Recent research published in the Journal of the American Medical Association has shown that the PrecivityAD2 test performs comparably to cerebrospinal fluid biomarkers and amyloid PET scans in detecting brain amyloid pathology.

C2N's tests are being recognised as a new standard for diagnosing Alzheimer’s disease. The PrecivityAD2 blood test achieved an accuracy rate of 90% or more, irrespective of whether patients were seen in primary or secondary care. In comparison, standard evaluation methods, such as patient history and routine tests, resulted in correct diagnoses of Alzheimer’s in only 61% of cases in primary care and 73% in specialist memory clinics.

C2N's new tests for tau tangle pathology will build on the demand generated by their existing Precivity tests.



Source: c2n.com

Report Abuse